Thus, from the therapeutic standpoint, our results reveal that targeting TRIB1 expression could, in addition to beneficially affecting OLR1 expression, moderate CHD pathogenesis by simultaneously altering in favorable directions the expression of a number of other disease-promoting genes affected by changes in TRIB1 expression. This evidence concerns the gene OLR1 and coronary artery disorder.